iCo Therapeutics Inc.

iCo Therapeutics Inc. (iCo) is a biotechnology company engaged in developing and commercializing drug candidates for treating ocular and systemic fungal diseases. The product pipeline of the company consists of three compounds namely iCo-007, iCo-008 and iCo-009. The iCo-009 is a proprietary oral formulation of amphotericin B for treatment of systemic fungal infections in immune-compromised patients such as human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), caner, transplant recipients, diabetics and some parasitical infections. Where as, iCo-008 (also known as Bertilimumab/CAT-213), is a human monoclonal antibody targeting eotaxin-1. iC0-007 is a new generation antisense candidate used for treatment of diabetic macular edema. The company also provides clinical trails study for pipeline development. iCo is headquartered in Vancouver, Canada.

Street: 
777 Hornby Street
City: 
Vancouver
Postcode: 
V6Z 1S4
Federal State : 
Canada
WebSite: 
www.icotherapeutics.com
Fax: 
1-604-6029699

Company Index Score

Current Index Score Historical Index Score
  • iCo Therapeutics Inc. currently scores 50 % in the index.
  • iCo Therapeutics Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • iCo Therapeutics Inc. is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets